ATE525081T1 - Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit - Google Patents

Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Info

Publication number
ATE525081T1
ATE525081T1 AT03711550T AT03711550T ATE525081T1 AT E525081 T1 ATE525081 T1 AT E525081T1 AT 03711550 T AT03711550 T AT 03711550T AT 03711550 T AT03711550 T AT 03711550T AT E525081 T1 ATE525081 T1 AT E525081T1
Authority
AT
Austria
Prior art keywords
upa
tpa
urokinase
peptides
regulating
Prior art date
Application number
AT03711550T
Other languages
English (en)
Inventor
Abd-Al-Roof Higazi
Original Assignee
Thrombotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/020077 external-priority patent/WO2003006042A1/en
Application filed by Thrombotech Ltd filed Critical Thrombotech Ltd
Application granted granted Critical
Publication of ATE525081T1 publication Critical patent/ATE525081T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03711550T 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit ATE525081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/063,046 US20030211095A1 (en) 2002-05-08 2002-05-08 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
PCT/US2002/020077 WO2003006042A1 (en) 2001-07-10 2002-06-24 Peptide for regulation of tissue plasminogen activator
PCT/US2003/007683 WO2003095476A2 (en) 2002-05-08 2003-03-12 PEPTIDES FOR REGULATION OF UROKINASE (uPA) AND TISSUE TYPE (tPA) PLASMINOGEN ACTIVATOR AND METHOD OF OPTIMIZING THERAPEUTIC EFFICACY

Publications (1)

Publication Number Publication Date
ATE525081T1 true ATE525081T1 (de) 2011-10-15

Family

ID=29399060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711550T ATE525081T1 (de) 2002-05-08 2003-03-12 Peptide zur regulierung von urokinase (upa) und gewebe- (tpa) plasminogenaktivator und verfahren zur optimierung der therapeutischen wirksamkeit

Country Status (10)

Country Link
US (1) US20030211095A1 (de)
EP (1) EP1507547B1 (de)
JP (1) JP2006502096A (de)
AT (1) ATE525081T1 (de)
AU (1) AU2003213856B2 (de)
CA (1) CA2488968C (de)
DK (1) DK1507547T3 (de)
ES (1) ES2373713T3 (de)
IL (1) IL165066A (de)
WO (1) WO2003095476A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263351A1 (en) * 2002-12-31 2006-11-23 The General Hospital Corporation Methods and compositions for protection against thrombolysis associated reperfusion injury
JP5421257B2 (ja) * 2007-07-24 2014-02-19 ディー−ファーム リミテッド プラスミノーゲン活性化因子阻害物質１由来のペプチドおよびその使用
CA2711878A1 (en) 2008-01-09 2009-07-16 Intrexon Corporation Therapeutic inhibitors of pai-1 function and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558010A (en) * 1980-04-03 1985-12-10 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom
EP0326151B1 (de) * 1988-01-29 1993-06-16 Sumitomo Pharmaceuticals Company, Limited Verbesserte Formulierungen mit kontrollierter Abgabe
US5130143A (en) * 1988-11-04 1992-07-14 The Research Foundation Of State University Of New York Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US6150332A (en) * 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
JP2001520200A (ja) * 1997-10-17 2001-10-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウロキナーゼタイプのプラスミノーゲン活性化因子の内在化および分解を促進するための組成物および方法
CA2453309A1 (en) * 2001-07-10 2003-01-23 Thrombotech Ltd. Peptide for regulation of tissue plasminogen activator

Also Published As

Publication number Publication date
EP1507547A2 (de) 2005-02-23
EP1507547B1 (de) 2011-09-21
IL165066A (en) 2011-03-31
WO2003095476A2 (en) 2003-11-20
IL165066A0 (en) 2005-12-18
CA2488968A1 (en) 2003-11-20
EP1507547A4 (de) 2007-03-14
JP2006502096A (ja) 2006-01-19
WO2003095476A3 (en) 2004-04-01
CA2488968C (en) 2013-10-29
AU2003213856A1 (en) 2003-11-11
US20030211095A1 (en) 2003-11-13
AU2003213856B2 (en) 2008-10-16
ES2373713T3 (es) 2012-02-08
DK1507547T3 (da) 2012-01-16

Similar Documents

Publication Publication Date Title
DeClerck et al. Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2
Bode The structure of thrombin: a janus-headed proteinase
ATE182336T1 (de) Peptidinhibitoren der urokinaserezeptor-aktivität
ES2031826T3 (es) Procedimiento para producir nuevos peptidos activadores del plasminogeno.
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DE60021715D1 (de) Phospahatasen mit verbesserter phytase-aktivität
MX9701869A (es) Inhibidor de la proteasa leucocitaria secretoria como inhibidor de la triptasa.
CA2563675A1 (en) Recombinantly modified plasmin
ATE417618T1 (de) Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
Schwartz Serum-derived growth factor is thrombin?
DK1507547T3 (da) Peptider til regulation af urokinaseplasminogenaktivator (UPA) og vævsplasminogenaktivator (TPA) og fremgangsmåde til optimering af terapeutisk effektivitet
EP0290118A3 (de) Fibrinolytisch wirksames Enzym
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
Mohanam et al. Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
Arza et al. Prostromelysin‐1 (proMMP‐3) stimulates plasminogen activation by tissue‐type plasminogen activator
DE69431603D1 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
DK0672150T3 (da) Modificeret Kluyveromyces-gær, fremstilling og anvendelse
ATE194360T1 (de) Verfahren und mittel für die herstellung von bindungsproteinen für inhibitoren von plasmaproteinasen
Campbell et al. Binding and activation of plasminogen on the surface of osteosarcoma cells
DK1379639T3 (da) Muse-glucuronyl-C5-epimerase, DNA der koder for samme, og anvendelser deraf
JP2004534842A5 (de)
Nowak et al. Effects of metal ions on activity of plasmin
DE60033297D1 (de) Für die humane untereinheit 5-ht3-c des serotoninrezeptors 5-ht3 kodierende dna
US7498410B2 (en) Bifunctional variants of recombinant tissue-type plasminogen activator with platelet aggregation inhibitory activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1507547

Country of ref document: EP